- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ibio Inc (IBIO)
Ibio Inc stock price live, this page displays NASDAQ IBIO stock exchange data. View the IBIO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Ibio Inc real time stock price chart below.
What Is the Ibio Inc Stock Price Today?
The Ibio Inc stock price today is 1.3100.
What Is the Stock Symbol for Ibio Inc?
The stock symbol for Ibio Inc is "IBIO."
What Stock Exchange Does Ibio Inc Trade On?
Ibio Inc is listed and trades on the NASDAQ stock exchange.
Is Ibio Inc a Good Stock to Buy?
Determining whether Ibio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IBIO quote. (ISIN: US4510337086)
What Is the Ibio Inc Stock Price Today?
The Ibio Inc stock price today is 1.3100.
What Is the Stock Symbol for Ibio Inc?
The stock symbol for Ibio Inc is "IBIO."
What Stock Exchange Does Ibio Inc Trade On?
Ibio Inc is listed and trades on the NASDAQ stock exchange.
Is Ibio Inc a Good Stock to Buy?
Determining whether Ibio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IBIO quote. (ISIN: US4510337086)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.2800
1.3300
52 wk Range
0.7708
3.8200
IBIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.28001.3300
52 wk Range
0.77083.8200
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IBIO Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
5.5250
Upside
+321.76%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Buy
Moving Averages
Strong Sell
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 5.5250
(+321.76% Upside)
Earnings
Latest Release
Aug 28, 2026
EPS / Forecast
-0.05 / -0.06
Revenue / Forecast
-- / 66.67K
Compare IBIO to Peers and Sector
Metrics to compare | IBIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIBIOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.5x | −2.1x | −0.4x | |
PEG Ratio | −0.03 | −0.19 | 0.00 | |
Price/Book | 1.0x | 3.2x | 2.6x | |
Price / LTM Sales | 842.4x | 166.9x | 3.1x | |
Upside (Analyst Target) | 319.8% | 384.7% | 48.9% | |
Fair Value Upside | Unlock | 3.2% | 6.8% | Unlock |
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company’s technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2–expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Ibio (IBIO) Stock Price Today?
The Ibio stock price today is 1.3100 USD.
What Stock Exchange Does Ibio Trade On?
Ibio is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Ibio?
The stock symbol for Ibio is "IBIO."
What Is the Ibio Market Cap?
As of today, Ibio market cap is 84.2400M USD.
What Is Ibio's Earnings Per Share (TTM)?
The Ibio EPS (TTM) is -0.3175.
When Is the Next Ibio Earnings Date?
Ibio will release its next earnings report on Nov 17, 2026.
From a Technical Analysis Perspective, Is IBIO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Ibio Stock Split?
Ibio has split 3 times.
How Many Employees Does Ibio Have?
Ibio has 23 employees.
What is the current trading status of Ibio (IBIO)?
As of Sep 06, 2026, Ibio (IBIO) is trading at a price of 1.3100 USD, with a previous close of 1.3000 USD. The stock has fluctuated within a day range of 1.2800 USD to 1.3300 USD, while its 52-week range spans from 0.7708 USD to 3.8200 USD.
What Is Ibio (IBIO) Price Target According to Analysts?
The average 12-month price target for Ibio is 5.5250 USD, with a high estimate of 7 USD and a low estimate of 4.2 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +321.76% Upside potential.
What Is the IBIO Premarket Price?
IBIO's last pre-market stock price is 1.3391 USD. The pre-market share volume is 1,810.0000, and the stock has decreased by 0.0391, or 3.0100%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.